SlideShare uma empresa Scribd logo
1 de 36
HIV -AIDS
with
CRYPTOCOCCAL MENINGITIS
Doney Joseph
PharmD Intern
 AIDS (Acquired immune deficiency syndrome) is a disease
caused by a virus called HIV (Human Immunodeficiency Virus).
 The illness alters the immune system, making people much
more vulnerable to infections and diseases.
 India has a population of 1.2 billion people, around half of
whom are adults in the sexually active age group
 The first AIDS case in India was detected in 1986 and since then
HIV infection has been reported in all states and union
territories..
 HIV is the virus which attacks the T-cells in the immune
system.
AIDS is the syndrome which appears in advanced
stages of HIV infection.
HIV is a virus.
AIDS is a medical condition
Stages of HIV
Stage 1
(Asymptomatic)
 Asymptomatic
 Persistent generalized
lymphadinopathy
Stage 2 (Mild)
 Unexplained moderate weight
loss (<10%)
 Recurrent respiratory tract
infections
 Herpes zoster
 Recurrent oral ulceration
 Papular pruritic eruptions
 Fungal nail infections
Staging of HIV is based
on OIs:
•STAGE 1
•STAGE 2
•Stage 3
•Stage 4
Stages of HIV
Advanced:
 Unexplained severe weight loss
(>10%)
 Unexplained chronic diarrhea for
longer than one month
 Unexplained persistent fever (above
37.5oC intermittent or constant for
longer than one month)
 Persistent oral candidiasis
 Pulmonary tuberculosis
 Severe bacterial infections,
 bacteraemia)
 Unexplained anaemia (<8 g/dl),
neutropenia (<0.5 X 109/litre) and or
chronic thrombocytopenia(<50 X
109/litre3)
•Stage 1
•Stage 2
•STAGE 3
•Stage 4
Stages of HIV
Severe:
 HIV wasting syndrome
 Pneumocystis pneumonia
 Recurrent severe bacterial
pneumonia
 Chronic herpes simplex infection
Oesophageal candidiasis (or
candidiasis of trachea, bronchi or
lungs)
 Extrapulmonary tuberculosis
 Cytomegalo virus infection
 Toxoplasmosis
 HIV encephalopathy
 Extrapulmonary cryptococcosis
including meningitis
 Disseminated non-tuberculous
mycobacteria infection
•Stage 1
•Stage 2
•Stage 3
•STAGE 4
First line ART regimens for adults, adolescents, pregnant and
breastfeeding women and children (June-2013 WHO CONSOLIDATED guidelines)
FIRST LINE ART PREFERRED FRIST
LINE REGIMENS
ALTERNATIVE FIRST LINE
REGIMENS
Adults
(Including pregnant women
and breastfeeding women and
adults with TB and HBV co
infection)
TDF+3TC+EFZ
ZDV + 3TC + EFV
ZDV + 3TC + NVP
TDF + 3TC + NVP
Adolescents (10 to 19 years)
≥35 kg
ZDV + 3TC + EFV
ZDV + 3TC + NVP
TDF + 3TC + NVP
ABC + 3TC + EFV (or NVP)
Children 3 years to less than
10
years and adolescents <35 kg ABC + 3TC + EFZ
ABC + 3TC + NVP
ZDV + 3TC + EFZ/NVP
TDF + 3TC + NVP/EFZ
Children <3 years ABC or
ZDV + 3TC + LPV/r
ABC + 3TC + NVP
ZDV + 3TC + NVP
Rationale and supporting evidence
(The move to TDF+3TC+EFZ as preferred first
line option)
 A systematic review comparing 6 regimens showed that a once daily combination
of TDF+3TC+EFZ is less frequently associated with severe adverse events and has
a better virological and treatment response compared with other once/twice
regimens. People receiving NVP are twice likely to discontinue treatment bcoz of
ADRs compared to EFZ
(www.who.int/hiv/pub/guidelines/arv2013/annexes)
When to start ART in Adults and adolescents
(June-2013 WHO CONSOLIDATED guidelines)
 ART should be initiated in all individuals with Severe and advanced HIV
clinical disease(WHO clinical stages 3 or 4) and individuals with cd4 count
less than on equal to 350cells/mm3.
 ART should be initiated in all individuals with HIV and CD4 count grater
than 350cells/mm3 and less than or equal to 500cells/mm3 regardless of
WHO clinical staging.
 ART should be initiated regardless of CD4 and Clinical staging in following
conditions:
1. Individuals with HIV and active TB
2. HIV and HBV infection with evidence of chronic liver disease.
3. Pregnant and breastfeeding women with HIV
Cryptococcal Meningitis?
 Cryptococcal meningitis is one of the most important opportunistic infections
and a major contributor to high mortality before and after ART is initiated.
 The infection is not contagious.
General symptoms includes:
Headache
Fever
Neck pain
Nausea and vomiting
Sensitivity to light
Altered mental status (Includes confusion to coma)
Age:45 years Unit: AKH
Sex: Male Weight:48 Kg
PMHx
 Patient is a k/c/o HIV since 5 years and on ART since 1 year (TDF+3TC+EFZ)
FHx:
 2 children –NR, wife –expired (7 yrs ago)
Reasons for admission:
 C/o fever, vomiting, headache since 1 week
 Difficulty in hearing and confusion (4 days)
Day 1
BP : 130/80mm Hg Pulse: 82 bpm
Temp:101f
o/e: CVS: S1 S2 +
RS:B/L NVBS +
CNS: Conscious disoriented
P/A:soft, non tender
Adv: Hb, TC, DC, Platelet count, ESR, S/E, IgG antibodies, CSF
analysis, India ink stain test, CD4 cells
Drug Dose Route
Frequency
IVF DNS WITH
MULTIVITAMIN dex:5g+Nacl:0.9g+MV
I:10ml
IV stat
T.Paracetamol 650mg PO SoS
Inj.Ondansetron 2mg IV SoS
Day 2
BP- 130/80mm Hg Pulse- 80bpm
Temp: 100f
o/e: vomiting decreased
CVS: S1 S2 +
RS:B/L NVBS+
P/A:soft, non tender
CNS: conscious disoriented
Adv: CST
Lab Parameters
Hematology
HB:12g%
WBC: 9000cells/mm3
N: 70%
L: 23%
M: 04%
E: 03%
PLT: 2.07 lakhscells/cumm
ESR: 80mm/hr
CSF analysis:
Glucose - 40mg/dl
Protein - 200mg/dl
WBC – 300 cells/μl
CD4 Count: 265 cells
Serum Electrolytes
Na : 134 mmol/L
K : 3.6 mmol/L
Cl : 101 mmol/L
Day 3
BP- 120/80mm Hg Pulse- 82bpm
o/e:
Afebrile
CVS: S1 S2 +
RS:B/L NVBS +
P/A:soft ,non tender
CNS: conscious disoriented
Lab Report:
AFB – Negative
India ink stain – Positive
IgG antibodies – Not detected
Drug Dose Route
Frequency
Fluconazole 400 mg PO 1-0-1
Amphotericin B 50 mg IV 1-0-0
Day 4,5
BP- 120/80mm Hg Pulse- 82bpm
o/e:
CVS: S1 S2 heard
RS:B/L NVBS Heard
P/A:soft, non tender
CNS: conscious disoriented
ADV:CST
Day 6
BP- 120/80mm Hg Pulse- 80bpm
o/e:
CVS: S1 S2 heard
RS:B/L NVBS Heard
P/A:soft ,non tender
CNS: conscious disorientation decreased
(able to hear without difficulty)
ADV: Continue
Pharmaceutical care plan
Subjective evidence Objective evidence
Headache CSF analysis
Vomiting India ink stain
Fever
Provisional Diagnosis
HIV
with
cryptococcal meningitis
Goals of the treatment
 Clinical goals: Prolongation of life and improvement in quality of life
 Virologic goals: Greatest possible reduction in viral load as long as possible
 Therapeutic goals:limiting drug toxicity and facilitating adherence.
Treatment Options
HIV
 Lamivudine+Tenofovir+Efavirenz
Fever-Paracetamol
Vomiting-Ondansetron
Cryptococcal meningitis
 Administer Amphotericin-B at 0.7-1mg/kg/day for 2 weeks with/without 2 weeks of
Flucytosine at 100mg/kg/day in 4 divided doses, followed by fluconazole at 400mg/day
for minimum of 8-10 weeks.
 Alternate initial therapy includes lipid formulation of Amphotericin-B in doses of 4-
6mg/kg/day for 3 weeks with fluconazole 400mg BID.
 {Treat Cryptococcal meningitis first, start ART when patient is stabilized or OI
treatment is completed}.
Goals Achieved
 Vomiting decreased by day 2
 Fever decreased by day 3
 Reduction in Hearing difficulty by day 6
Monitoring Parameters
Disease:
 Viral load (every 6 months after ART and every 12 months thereafter)
{June-2013 WHO guidelines}
 CD4 count if viral load not available.
Drugs:
 Renal function tests (TDF,3TC, Fluconazole, Amphotericin-B)
 Serum transaminases, cholesterol (EFZ,)
 Liver function tests (Fluconazole, Amphotericin-B)
 Potassium levels (Fluconazole, Amphotericin-B)
Problems Identified
Nill
Patient counseling
 About disease
This particular virus can only infect human beings
HIV weakens immune system by destroying important cells that fight disease and
infection. A "deficient" immune system can't protect the person.
About drugs:
Importance of medication adherence.
 Mobile phone text messages could be considered as a reminder tool
for promoting adherence to ART as part of a package of adherence
interventions (June 2013 WHO guidelines)
 If missed doses (even 2 doses in a month) DRUG
RESISTANCE can develop. This is bad for the patient
(These drugs will stop working.)
 Drugs must be taken twice daily, and miss no doses.
 If forget a dose, do not take a double dose.
 Drugs MUST NOT be shared with family and friends.
Life style modification:
 THANK..UUUUU

Mais conteúdo relacionado

Mais procurados

August 2013 PLUS HIV Treatment
August 2013 PLUS HIV TreatmentAugust 2013 PLUS HIV Treatment
August 2013 PLUS HIV TreatmentPositive_Force
 
Human Immunodeficiency Virus Presentation
Human Immunodeficiency Virus PresentationHuman Immunodeficiency Virus Presentation
Human Immunodeficiency Virus Presentationbrinkwar
 
Personized hiv therapy ppt
Personized hiv therapy pptPersonized hiv therapy ppt
Personized hiv therapy pptSrilaxmiMenon
 
Highly active antiretroviral therapy incidence of adverse drug reactions
Highly active antiretroviral therapy incidence of adverse drug reactionsHighly active antiretroviral therapy incidence of adverse drug reactions
Highly active antiretroviral therapy incidence of adverse drug reactionspharmaindexing
 
Revised Pediatric Tuberculosis guidelines (NTEP) 2020
Revised Pediatric Tuberculosis guidelines (NTEP) 2020Revised Pediatric Tuberculosis guidelines (NTEP) 2020
Revised Pediatric Tuberculosis guidelines (NTEP) 2020Sonali Paradhi Mhatre
 
Highly active antiretroviral therapy
Highly active antiretroviral therapyHighly active antiretroviral therapy
Highly active antiretroviral therapyAbhishek Gupta
 
Case Presentation Dengue Fever
Case Presentation Dengue FeverCase Presentation Dengue Fever
Case Presentation Dengue FeverZain Khan
 
Tb And Ltbi Treatment
Tb And Ltbi TreatmentTb And Ltbi Treatment
Tb And Ltbi Treatmentghalan
 
Revised TB programme India
Revised TB programme IndiaRevised TB programme India
Revised TB programme Indiaarnab ghosh
 
Chinmoy tb presentation
Chinmoy tb presentationChinmoy tb presentation
Chinmoy tb presentationChinmoy Lath
 
HIV UPDATE TREATMENT
HIV UPDATE TREATMENTHIV UPDATE TREATMENT
HIV UPDATE TREATMENTrafa64
 
MDR Tuberculosis Case Presentation & Some facts About MDR/XDR TB
MDR Tuberculosis Case Presentation & Some facts About MDR/XDR TBMDR Tuberculosis Case Presentation & Some facts About MDR/XDR TB
MDR Tuberculosis Case Presentation & Some facts About MDR/XDR TBSMS Medical College, Jaipur
 

Mais procurados (20)

August 2013 PLUS HIV Treatment
August 2013 PLUS HIV TreatmentAugust 2013 PLUS HIV Treatment
August 2013 PLUS HIV Treatment
 
HIV Treatment and PrEP in 2015
HIV Treatment and PrEP in 2015HIV Treatment and PrEP in 2015
HIV Treatment and PrEP in 2015
 
A case of MDR-TB
A case of MDR-TBA case of MDR-TB
A case of MDR-TB
 
Human Immunodeficiency Virus Presentation
Human Immunodeficiency Virus PresentationHuman Immunodeficiency Virus Presentation
Human Immunodeficiency Virus Presentation
 
Pharmacology in HIV
Pharmacology in HIVPharmacology in HIV
Pharmacology in HIV
 
Personized hiv therapy ppt
Personized hiv therapy pptPersonized hiv therapy ppt
Personized hiv therapy ppt
 
Hiv2 art 2018
Hiv2 art 2018Hiv2 art 2018
Hiv2 art 2018
 
Highly active antiretroviral therapy incidence of adverse drug reactions
Highly active antiretroviral therapy incidence of adverse drug reactionsHighly active antiretroviral therapy incidence of adverse drug reactions
Highly active antiretroviral therapy incidence of adverse drug reactions
 
Treatment for HIV infection
Treatment for HIV infectionTreatment for HIV infection
Treatment for HIV infection
 
Revised Pediatric Tuberculosis guidelines (NTEP) 2020
Revised Pediatric Tuberculosis guidelines (NTEP) 2020Revised Pediatric Tuberculosis guidelines (NTEP) 2020
Revised Pediatric Tuberculosis guidelines (NTEP) 2020
 
Highly active antiretroviral therapy
Highly active antiretroviral therapyHighly active antiretroviral therapy
Highly active antiretroviral therapy
 
Case Presentation Dengue Fever
Case Presentation Dengue FeverCase Presentation Dengue Fever
Case Presentation Dengue Fever
 
Tb And Ltbi Treatment
Tb And Ltbi TreatmentTb And Ltbi Treatment
Tb And Ltbi Treatment
 
Revised TB programme India
Revised TB programme IndiaRevised TB programme India
Revised TB programme India
 
Chinmoy tb presentation
Chinmoy tb presentationChinmoy tb presentation
Chinmoy tb presentation
 
HIV UPDATE TREATMENT
HIV UPDATE TREATMENTHIV UPDATE TREATMENT
HIV UPDATE TREATMENT
 
MDR Tuberculosis Case Presentation & Some facts About MDR/XDR TB
MDR Tuberculosis Case Presentation & Some facts About MDR/XDR TBMDR Tuberculosis Case Presentation & Some facts About MDR/XDR TB
MDR Tuberculosis Case Presentation & Some facts About MDR/XDR TB
 
Rntcp
Rntcp  Rntcp
Rntcp
 
AIDS
AIDSAIDS
AIDS
 
4.Dots
4.Dots4.Dots
4.Dots
 

Destaque

Aids the threat today / dental implant courses
Aids   the threat today / dental implant coursesAids   the threat today / dental implant courses
Aids the threat today / dental implant coursesIndian dental academy
 
Dental healthcare associated infections an overview of pathogens, risks and c...
Dental healthcare associated infections an overview of pathogens, risks and c...Dental healthcare associated infections an overview of pathogens, risks and c...
Dental healthcare associated infections an overview of pathogens, risks and c...Dana Sinziana Brehar-Cioflec
 
Infection Control In Dentistry
Infection Control In DentistryInfection Control In Dentistry
Infection Control In DentistryJawad Shah
 
Hiv Hcv Coinfected Patient
Hiv Hcv Coinfected PatientHiv Hcv Coinfected Patient
Hiv Hcv Coinfected Patientshabeel pn
 
MANAGEMENT OF MEDICALLY COMPROMISED CHILD IN DENTISTRY
MANAGEMENT OF MEDICALLY COMPROMISED CHILD IN DENTISTRYMANAGEMENT OF MEDICALLY COMPROMISED CHILD IN DENTISTRY
MANAGEMENT OF MEDICALLY COMPROMISED CHILD IN DENTISTRYPAVAN KUMAR Sinsinwar
 
Occupational hazards in dentistry
Occupational hazards in dentistryOccupational hazards in dentistry
Occupational hazards in dentistrySuditi Acharya
 
Cross infection control in dentistry (Few basic points)
Cross infection control in dentistry (Few basic points)Cross infection control in dentistry (Few basic points)
Cross infection control in dentistry (Few basic points)Sumaiya Hasan
 
Oral manifestations in hiv disease
Oral manifestations in hiv diseaseOral manifestations in hiv disease
Oral manifestations in hiv diseasePraveena Veena
 
Dental considerations in pregnant women
Dental considerations in pregnant womenDental considerations in pregnant women
Dental considerations in pregnant womenDr.Tanmay Singh
 
Infection Control in Dentistry
Infection Control in DentistryInfection Control in Dentistry
Infection Control in DentistryMedicineAndFamily
 
Manag of pregnant woman in dental clinic
Manag of pregnant woman in dental clinicManag of pregnant woman in dental clinic
Manag of pregnant woman in dental clinicimelhakim
 
Counselling HIV/ AIDS patient
Counselling HIV/ AIDS patient Counselling HIV/ AIDS patient
Counselling HIV/ AIDS patient Qurrot Ulain Taher
 
Review on dental management of pregnant patient
Review on dental management of pregnant patientReview on dental management of pregnant patient
Review on dental management of pregnant patientTanzir Hasan
 
DENTAL MANAGEMENT OF THE MEDICALLY COMPROMISED PATIENT DENTAL MANAGEMENT OF...
DENTAL MANAGEMENT OF THE MEDICALLY COMPROMISED PATIENT 	 DENTAL MANAGEMENT OF...DENTAL MANAGEMENT OF THE MEDICALLY COMPROMISED PATIENT 	 DENTAL MANAGEMENT OF...
DENTAL MANAGEMENT OF THE MEDICALLY COMPROMISED PATIENT DENTAL MANAGEMENT OF...MedicineAndFamily
 

Destaque (20)

Innovations in providing oral health services to hiv positive persons
Innovations in providing oral health services to hiv positive personsInnovations in providing oral health services to hiv positive persons
Innovations in providing oral health services to hiv positive persons
 
Aids the threat today / dental implant courses
Aids   the threat today / dental implant coursesAids   the threat today / dental implant courses
Aids the threat today / dental implant courses
 
Hiv/endodontic courses
Hiv/endodontic coursesHiv/endodontic courses
Hiv/endodontic courses
 
Hiv infection/ dental courses
Hiv infection/ dental coursesHiv infection/ dental courses
Hiv infection/ dental courses
 
Dental healthcare associated infections an overview of pathogens, risks and c...
Dental healthcare associated infections an overview of pathogens, risks and c...Dental healthcare associated infections an overview of pathogens, risks and c...
Dental healthcare associated infections an overview of pathogens, risks and c...
 
Infection Control In Dentistry
Infection Control In DentistryInfection Control In Dentistry
Infection Control In Dentistry
 
HIV AIDS
HIV AIDSHIV AIDS
HIV AIDS
 
Hiv Hcv Coinfected Patient
Hiv Hcv Coinfected PatientHiv Hcv Coinfected Patient
Hiv Hcv Coinfected Patient
 
MANAGEMENT OF MEDICALLY COMPROMISED CHILD IN DENTISTRY
MANAGEMENT OF MEDICALLY COMPROMISED CHILD IN DENTISTRYMANAGEMENT OF MEDICALLY COMPROMISED CHILD IN DENTISTRY
MANAGEMENT OF MEDICALLY COMPROMISED CHILD IN DENTISTRY
 
Occupational hazards in dentistry
Occupational hazards in dentistryOccupational hazards in dentistry
Occupational hazards in dentistry
 
Aids & dentistry
Aids & dentistryAids & dentistry
Aids & dentistry
 
HIV Dental
HIV DentalHIV Dental
HIV Dental
 
Cross infection control in dentistry (Few basic points)
Cross infection control in dentistry (Few basic points)Cross infection control in dentistry (Few basic points)
Cross infection control in dentistry (Few basic points)
 
Oral manifestations in hiv disease
Oral manifestations in hiv diseaseOral manifestations in hiv disease
Oral manifestations in hiv disease
 
Dental considerations in pregnant women
Dental considerations in pregnant womenDental considerations in pregnant women
Dental considerations in pregnant women
 
Infection Control in Dentistry
Infection Control in DentistryInfection Control in Dentistry
Infection Control in Dentistry
 
Manag of pregnant woman in dental clinic
Manag of pregnant woman in dental clinicManag of pregnant woman in dental clinic
Manag of pregnant woman in dental clinic
 
Counselling HIV/ AIDS patient
Counselling HIV/ AIDS patient Counselling HIV/ AIDS patient
Counselling HIV/ AIDS patient
 
Review on dental management of pregnant patient
Review on dental management of pregnant patientReview on dental management of pregnant patient
Review on dental management of pregnant patient
 
DENTAL MANAGEMENT OF THE MEDICALLY COMPROMISED PATIENT DENTAL MANAGEMENT OF...
DENTAL MANAGEMENT OF THE MEDICALLY COMPROMISED PATIENT 	 DENTAL MANAGEMENT OF...DENTAL MANAGEMENT OF THE MEDICALLY COMPROMISED PATIENT 	 DENTAL MANAGEMENT OF...
DENTAL MANAGEMENT OF THE MEDICALLY COMPROMISED PATIENT DENTAL MANAGEMENT OF...
 

Semelhante a Aids case

Anti retroviral therapy in children
Anti retroviral therapy  in childrenAnti retroviral therapy  in children
Anti retroviral therapy in childrensubhash chettri
 
Tuberculosis Treatment Symposia - The CRUDEM Foundation
Tuberculosis Treatment Symposia - The CRUDEM FoundationTuberculosis Treatment Symposia - The CRUDEM Foundation
Tuberculosis Treatment Symposia - The CRUDEM FoundationThe CRUDEM Foundation
 
C5 Case Study Session of Three Long-Term Survivors with HIV Disease Mondy
C5 Case Study Session of Three Long-Term Survivors with HIV Disease MondyC5 Case Study Session of Three Long-Term Survivors with HIV Disease Mondy
C5 Case Study Session of Three Long-Term Survivors with HIV Disease MondyDSHS
 
Paediatric HIV.ppt
Paediatric HIV.pptPaediatric HIV.ppt
Paediatric HIV.pptMr Barasa
 
HIV and TB coinfection
HIV and TB coinfectionHIV and TB coinfection
HIV and TB coinfectionswati2084
 
REVIEW ON HIV ON THE CURRENT BASIS DATA .pptx
REVIEW ON HIV ON THE CURRENT BASIS DATA  .pptxREVIEW ON HIV ON THE CURRENT BASIS DATA  .pptx
REVIEW ON HIV ON THE CURRENT BASIS DATA .pptxGCHANDRASAIKUMAR
 
GFATM training for nurses
GFATM training for nursesGFATM training for nurses
GFATM training for nursesanjalatchi
 
GFATM trainning for Nurses.pptx
GFATM trainning for Nurses.pptxGFATM trainning for Nurses.pptx
GFATM trainning for Nurses.pptxnaveenithkrishnan
 
Antitubercular Agents
Antitubercular AgentsAntitubercular Agents
Antitubercular Agentsgirlie
 
Seminar on hiv diagnosis and management by Dr Sohanlal Sharma
Seminar on hiv diagnosis and management by Dr Sohanlal SharmaSeminar on hiv diagnosis and management by Dr Sohanlal Sharma
Seminar on hiv diagnosis and management by Dr Sohanlal SharmaPradeep Singh
 
hiv ,peads, pediatric Hiv managment ( managment of HIV in children)
hiv ,peads, pediatric Hiv managment ( managment of HIV in children)hiv ,peads, pediatric Hiv managment ( managment of HIV in children)
hiv ,peads, pediatric Hiv managment ( managment of HIV in children)Nehal Shah
 
Pulmonary TB (Tuberculosis) PPT SlideShare
Pulmonary TB  (Tuberculosis) PPT SlideSharePulmonary TB  (Tuberculosis) PPT SlideShare
Pulmonary TB (Tuberculosis) PPT SlideSharesonam
 
Hiv presentation pdf copy
Hiv presentation pdf copyHiv presentation pdf copy
Hiv presentation pdf copyRama shankar
 
ART & NACO GUIDELINES for treatment of hiv
ART & NACO GUIDELINES for treatment of hivART & NACO GUIDELINES for treatment of hiv
ART & NACO GUIDELINES for treatment of hivDRABHISHEKGUPTA16
 
Case history id forum tb & hiv
Case history id forum tb & hivCase history id forum tb & hiv
Case history id forum tb & hivhythemhashim
 
HIV guidelines in Namibia- a guide on the approach
HIV guidelines in Namibia- a guide on the approachHIV guidelines in Namibia- a guide on the approach
HIV guidelines in Namibia- a guide on the approachMekeKaale
 
HIV Pharmacotherapy in Pregnancy
HIV Pharmacotherapy in PregnancyHIV Pharmacotherapy in Pregnancy
HIV Pharmacotherapy in Pregnancydbridley
 

Semelhante a Aids case (20)

Anti retroviral therapy in children
Anti retroviral therapy  in childrenAnti retroviral therapy  in children
Anti retroviral therapy in children
 
Tuberculosis Treatment Symposia - The CRUDEM Foundation
Tuberculosis Treatment Symposia - The CRUDEM FoundationTuberculosis Treatment Symposia - The CRUDEM Foundation
Tuberculosis Treatment Symposia - The CRUDEM Foundation
 
C5 Case Study Session of Three Long-Term Survivors with HIV Disease Mondy
C5 Case Study Session of Three Long-Term Survivors with HIV Disease MondyC5 Case Study Session of Three Long-Term Survivors with HIV Disease Mondy
C5 Case Study Session of Three Long-Term Survivors with HIV Disease Mondy
 
Hiv.ppt
Hiv.pptHiv.ppt
Hiv.ppt
 
Paediatric HIV.ppt
Paediatric HIV.pptPaediatric HIV.ppt
Paediatric HIV.ppt
 
HIV and TB coinfection
HIV and TB coinfectionHIV and TB coinfection
HIV and TB coinfection
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
REVIEW ON HIV ON THE CURRENT BASIS DATA .pptx
REVIEW ON HIV ON THE CURRENT BASIS DATA  .pptxREVIEW ON HIV ON THE CURRENT BASIS DATA  .pptx
REVIEW ON HIV ON THE CURRENT BASIS DATA .pptx
 
GFATM training for nurses
GFATM training for nursesGFATM training for nurses
GFATM training for nurses
 
GFATM trainning for Nurses.pptx
GFATM trainning for Nurses.pptxGFATM trainning for Nurses.pptx
GFATM trainning for Nurses.pptx
 
Antitubercular Agents
Antitubercular AgentsAntitubercular Agents
Antitubercular Agents
 
Seminar on hiv diagnosis and management by Dr Sohanlal Sharma
Seminar on hiv diagnosis and management by Dr Sohanlal SharmaSeminar on hiv diagnosis and management by Dr Sohanlal Sharma
Seminar on hiv diagnosis and management by Dr Sohanlal Sharma
 
hiv ,peads, pediatric Hiv managment ( managment of HIV in children)
hiv ,peads, pediatric Hiv managment ( managment of HIV in children)hiv ,peads, pediatric Hiv managment ( managment of HIV in children)
hiv ,peads, pediatric Hiv managment ( managment of HIV in children)
 
Pulmonary TB (Tuberculosis) PPT SlideShare
Pulmonary TB  (Tuberculosis) PPT SlideSharePulmonary TB  (Tuberculosis) PPT SlideShare
Pulmonary TB (Tuberculosis) PPT SlideShare
 
Hiv presentation pdf copy
Hiv presentation pdf copyHiv presentation pdf copy
Hiv presentation pdf copy
 
ART & NACO GUIDELINES for treatment of hiv
ART & NACO GUIDELINES for treatment of hivART & NACO GUIDELINES for treatment of hiv
ART & NACO GUIDELINES for treatment of hiv
 
alp hiv 2
alp hiv 2alp hiv 2
alp hiv 2
 
Case history id forum tb & hiv
Case history id forum tb & hivCase history id forum tb & hiv
Case history id forum tb & hiv
 
HIV guidelines in Namibia- a guide on the approach
HIV guidelines in Namibia- a guide on the approachHIV guidelines in Namibia- a guide on the approach
HIV guidelines in Namibia- a guide on the approach
 
HIV Pharmacotherapy in Pregnancy
HIV Pharmacotherapy in PregnancyHIV Pharmacotherapy in Pregnancy
HIV Pharmacotherapy in Pregnancy
 

Aids case

  • 2.  AIDS (Acquired immune deficiency syndrome) is a disease caused by a virus called HIV (Human Immunodeficiency Virus).  The illness alters the immune system, making people much more vulnerable to infections and diseases.  India has a population of 1.2 billion people, around half of whom are adults in the sexually active age group  The first AIDS case in India was detected in 1986 and since then HIV infection has been reported in all states and union territories..
  • 3.  HIV is the virus which attacks the T-cells in the immune system. AIDS is the syndrome which appears in advanced stages of HIV infection. HIV is a virus. AIDS is a medical condition
  • 4.
  • 5. Stages of HIV Stage 1 (Asymptomatic)  Asymptomatic  Persistent generalized lymphadinopathy Stage 2 (Mild)  Unexplained moderate weight loss (<10%)  Recurrent respiratory tract infections  Herpes zoster  Recurrent oral ulceration  Papular pruritic eruptions  Fungal nail infections Staging of HIV is based on OIs: •STAGE 1 •STAGE 2 •Stage 3 •Stage 4
  • 6. Stages of HIV Advanced:  Unexplained severe weight loss (>10%)  Unexplained chronic diarrhea for longer than one month  Unexplained persistent fever (above 37.5oC intermittent or constant for longer than one month)  Persistent oral candidiasis  Pulmonary tuberculosis  Severe bacterial infections,  bacteraemia)  Unexplained anaemia (<8 g/dl), neutropenia (<0.5 X 109/litre) and or chronic thrombocytopenia(<50 X 109/litre3) •Stage 1 •Stage 2 •STAGE 3 •Stage 4
  • 7. Stages of HIV Severe:  HIV wasting syndrome  Pneumocystis pneumonia  Recurrent severe bacterial pneumonia  Chronic herpes simplex infection Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs)  Extrapulmonary tuberculosis  Cytomegalo virus infection  Toxoplasmosis  HIV encephalopathy  Extrapulmonary cryptococcosis including meningitis  Disseminated non-tuberculous mycobacteria infection •Stage 1 •Stage 2 •Stage 3 •STAGE 4
  • 8. First line ART regimens for adults, adolescents, pregnant and breastfeeding women and children (June-2013 WHO CONSOLIDATED guidelines) FIRST LINE ART PREFERRED FRIST LINE REGIMENS ALTERNATIVE FIRST LINE REGIMENS Adults (Including pregnant women and breastfeeding women and adults with TB and HBV co infection) TDF+3TC+EFZ ZDV + 3TC + EFV ZDV + 3TC + NVP TDF + 3TC + NVP Adolescents (10 to 19 years) ≥35 kg ZDV + 3TC + EFV ZDV + 3TC + NVP TDF + 3TC + NVP ABC + 3TC + EFV (or NVP) Children 3 years to less than 10 years and adolescents <35 kg ABC + 3TC + EFZ ABC + 3TC + NVP ZDV + 3TC + EFZ/NVP TDF + 3TC + NVP/EFZ Children <3 years ABC or ZDV + 3TC + LPV/r ABC + 3TC + NVP ZDV + 3TC + NVP
  • 9. Rationale and supporting evidence (The move to TDF+3TC+EFZ as preferred first line option)  A systematic review comparing 6 regimens showed that a once daily combination of TDF+3TC+EFZ is less frequently associated with severe adverse events and has a better virological and treatment response compared with other once/twice regimens. People receiving NVP are twice likely to discontinue treatment bcoz of ADRs compared to EFZ (www.who.int/hiv/pub/guidelines/arv2013/annexes)
  • 10. When to start ART in Adults and adolescents (June-2013 WHO CONSOLIDATED guidelines)  ART should be initiated in all individuals with Severe and advanced HIV clinical disease(WHO clinical stages 3 or 4) and individuals with cd4 count less than on equal to 350cells/mm3.  ART should be initiated in all individuals with HIV and CD4 count grater than 350cells/mm3 and less than or equal to 500cells/mm3 regardless of WHO clinical staging.  ART should be initiated regardless of CD4 and Clinical staging in following conditions: 1. Individuals with HIV and active TB 2. HIV and HBV infection with evidence of chronic liver disease. 3. Pregnant and breastfeeding women with HIV
  • 11. Cryptococcal Meningitis?  Cryptococcal meningitis is one of the most important opportunistic infections and a major contributor to high mortality before and after ART is initiated.  The infection is not contagious. General symptoms includes: Headache Fever Neck pain Nausea and vomiting Sensitivity to light Altered mental status (Includes confusion to coma)
  • 12. Age:45 years Unit: AKH Sex: Male Weight:48 Kg
  • 13. PMHx  Patient is a k/c/o HIV since 5 years and on ART since 1 year (TDF+3TC+EFZ) FHx:  2 children –NR, wife –expired (7 yrs ago)
  • 14. Reasons for admission:  C/o fever, vomiting, headache since 1 week  Difficulty in hearing and confusion (4 days)
  • 15. Day 1 BP : 130/80mm Hg Pulse: 82 bpm Temp:101f o/e: CVS: S1 S2 + RS:B/L NVBS + CNS: Conscious disoriented P/A:soft, non tender Adv: Hb, TC, DC, Platelet count, ESR, S/E, IgG antibodies, CSF analysis, India ink stain test, CD4 cells
  • 16. Drug Dose Route Frequency IVF DNS WITH MULTIVITAMIN dex:5g+Nacl:0.9g+MV I:10ml IV stat T.Paracetamol 650mg PO SoS Inj.Ondansetron 2mg IV SoS
  • 17. Day 2 BP- 130/80mm Hg Pulse- 80bpm Temp: 100f o/e: vomiting decreased CVS: S1 S2 + RS:B/L NVBS+ P/A:soft, non tender CNS: conscious disoriented Adv: CST
  • 18. Lab Parameters Hematology HB:12g% WBC: 9000cells/mm3 N: 70% L: 23% M: 04% E: 03% PLT: 2.07 lakhscells/cumm ESR: 80mm/hr CSF analysis: Glucose - 40mg/dl Protein - 200mg/dl WBC – 300 cells/μl CD4 Count: 265 cells Serum Electrolytes Na : 134 mmol/L K : 3.6 mmol/L Cl : 101 mmol/L
  • 19. Day 3 BP- 120/80mm Hg Pulse- 82bpm o/e: Afebrile CVS: S1 S2 + RS:B/L NVBS + P/A:soft ,non tender CNS: conscious disoriented Lab Report: AFB – Negative India ink stain – Positive IgG antibodies – Not detected
  • 20. Drug Dose Route Frequency Fluconazole 400 mg PO 1-0-1 Amphotericin B 50 mg IV 1-0-0
  • 21. Day 4,5 BP- 120/80mm Hg Pulse- 82bpm o/e: CVS: S1 S2 heard RS:B/L NVBS Heard P/A:soft, non tender CNS: conscious disoriented ADV:CST
  • 22. Day 6 BP- 120/80mm Hg Pulse- 80bpm o/e: CVS: S1 S2 heard RS:B/L NVBS Heard P/A:soft ,non tender CNS: conscious disorientation decreased (able to hear without difficulty) ADV: Continue
  • 24. Subjective evidence Objective evidence Headache CSF analysis Vomiting India ink stain Fever
  • 26. Goals of the treatment  Clinical goals: Prolongation of life and improvement in quality of life  Virologic goals: Greatest possible reduction in viral load as long as possible  Therapeutic goals:limiting drug toxicity and facilitating adherence.
  • 28. Cryptococcal meningitis  Administer Amphotericin-B at 0.7-1mg/kg/day for 2 weeks with/without 2 weeks of Flucytosine at 100mg/kg/day in 4 divided doses, followed by fluconazole at 400mg/day for minimum of 8-10 weeks.  Alternate initial therapy includes lipid formulation of Amphotericin-B in doses of 4- 6mg/kg/day for 3 weeks with fluconazole 400mg BID.  {Treat Cryptococcal meningitis first, start ART when patient is stabilized or OI treatment is completed}.
  • 29. Goals Achieved  Vomiting decreased by day 2  Fever decreased by day 3  Reduction in Hearing difficulty by day 6
  • 30. Monitoring Parameters Disease:  Viral load (every 6 months after ART and every 12 months thereafter) {June-2013 WHO guidelines}  CD4 count if viral load not available. Drugs:  Renal function tests (TDF,3TC, Fluconazole, Amphotericin-B)  Serum transaminases, cholesterol (EFZ,)  Liver function tests (Fluconazole, Amphotericin-B)  Potassium levels (Fluconazole, Amphotericin-B)
  • 32. Patient counseling  About disease This particular virus can only infect human beings HIV weakens immune system by destroying important cells that fight disease and infection. A "deficient" immune system can't protect the person.
  • 33. About drugs: Importance of medication adherence.  Mobile phone text messages could be considered as a reminder tool for promoting adherence to ART as part of a package of adherence interventions (June 2013 WHO guidelines)  If missed doses (even 2 doses in a month) DRUG RESISTANCE can develop. This is bad for the patient (These drugs will stop working.)  Drugs must be taken twice daily, and miss no doses.  If forget a dose, do not take a double dose.  Drugs MUST NOT be shared with family and friends.
  • 35.